Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 09/03/18 at 12:35pm

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter here in the UK. So there's the hope that Spring is just around the corner as we pass another Friday and another top ten rundown of the week's most popular articles.

There was massive news in the ongoing opioid crisis in the US, with a study discovering that, as emergency room visits as a result of overdoses relating to the drugs continue to rise, the dangerous class of medication does not present any benefits in pain management over traditional painkillers, calling into question why the health industry has been taking such huge risks by prescribing them.

And also on the topic of dangerous medications, it has emerged that Abbvie and Biogen have withdrawn their MS treatment Zinbryta from markets worldwide after an EMA safety review discovered 12 cases of serious inflammatory brain disorders relating to its use.

But, perhaps unsurprisingly, the most popular story in a week which contained International Women's Day concerned some pretty horrific allegations of sexual misconduct by a former Sanofi exec, who has been seeking a lofty sum for what he sees as unfair treatment.

Check out the week's ten most popular articles on here:

10. NHS trials "world-leading" initiative to cut prostate cancer diagnoses to just days

The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than one week by trialling a “world-leading” approach which leverages a new, more accurate scanning method.

9. Ontruzant launches to become first Herceptin biosimilar available in the UK

Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK, becoming the first biologic copycat version of Roche’s blockbuster to be available in the region.

8. Europe approves first therapy for haemophilia A with inhibitors in over 20 years

Roche has revealed that Hemlibra has been approved by the European Commission (EC) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.

7. Uncovering trends in the future of real world data

A new report has canvassed the intentions of industry players in the use of real world data and evidence over the coming years. Matt Fellows speaks to the study’s lead author and executives at Amgen and AstraZeneca to interpret how they expect the space to develop.

6. Japan saves record $12.2bn in 2017 through greater generic use

Japan is estimated to have saved ¥1.3 trillion ($12.2 billion) throughout the course of the fiscal year 2017 through its efforts to shift to greater use of generic products.

5. Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory

Celgene has inked a partnership with biotech firm Vividion Therapeutics to identify and develop small molecules as a treatment in oncological, inflammatory and neurodegenerative conditions.

4. Opioids are no more effective than common painkillers, study reveals

A new study has found that, for all their risks, opioids are no more effective than traditional non-steroidal anti-inflammatory drugs (NSAIDs) at easing chronic pain or at improving the extent to which this pain interferes with daily life.

3. Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review

Biogen and Abbvie are to voluntarily withdraw their multiple sclerosis therapy Zinbryta from all global markets following the decision by the European Medicines Agency to launch an urgent safety review.

2. Gilead investigational data gives hope for HIV eradication in humans

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of TLR7 agonist GS-9620 and bNAb PGT121 in the eradication of HIV in non-human primates.

1. Former Sanofi exec accused of sexting and indecent exposure demands €1.2m

A former Sanofi executive fired for sexting, indecent exposure and other alleged sexual harassment charges has been demanding up to €1.2 million through legal action arguing against his unfair dismissal for gross misconduct in August 2013.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches